Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.
Najarian D, Sanga P, Wang S, Lim P, Singh A, Robertson MJ, Cohen K, Schotte A, Milz R, Venkatasubramanian R, T'Jollyn H, Walling DP, Galderisi S, Gopal S. Najarian D, et al. Among authors: t jollyn h. Int J Neuropsychopharmacol. 2022 Mar 17;25(3):238-251. doi: 10.1093/ijnp/pyab071. Int J Neuropsychopharmacol. 2022. PMID: 34791283 Free PMC article. Clinical Trial.
Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.
T'jollyn H, Ackaert O, Chien C, Lopez-Gitlitz A, McCarthy S, Ruixo CP, Karsh L, Chi K, Chowdhury S, Ruixo JP, Agarwal N. T'jollyn H, et al. Cancer Chemother Pharmacol. 2022 May;89(5):629-641. doi: 10.1007/s00280-022-04427-1. Epub 2022 Apr 2. Cancer Chemother Pharmacol. 2022. PMID: 35366072 Clinical Trial.
First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers.
Felip E, Moreno V, Morgensztern D, Curigliano G, Rutkowski P, Trigo JM, Calvo A, Kowalski D, Cortinovis D, Plummer R, Maio M, Ascierto PA, Vladimirov VI, Cervantes A, Zudaire E, Hazra A, T'jollyn H, Bandyopadhyay N, Greger JG, Attiyeh E, Xie H, Calvo E. Felip E, et al. Among authors: t jollyn h. Cancer Chemother Pharmacol. 2022 Apr;89(4):499-514. doi: 10.1007/s00280-022-04414-6. Epub 2022 Mar 17. Cancer Chemother Pharmacol. 2022. PMID: 35298698 Free PMC article. Clinical Trial.
Moxifloxacin dosing in post-bariatric surgery patients.
Colin P, Eleveld DJ, Struys MM, T'Jollyn H, Bortel LM, Ruige J, De Waele J, Van Bocxlaer J, Boussery K. Colin P, et al. Br J Clin Pharmacol. 2014 Jul;78(1):84-93. doi: 10.1111/bcp.12302. Br J Clin Pharmacol. 2014. PMID: 24313873 Free PMC article. Clinical Trial.
Physiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.
T'jollyn H, Snoeys J, Vermeulen A, Michelet R, Cuyckens F, Mannens G, Van Peer A, Annaert P, Allegaert K, Van Bocxlaer J, Boussery K. T'jollyn H, et al. AAPS J. 2015 Nov;17(6):1376-87. doi: 10.1208/s12248-015-9803-z. Epub 2015 Jul 25. AAPS J. 2015. PMID: 26209290 Free PMC article.
Strategies for Determining Correct Cytochrome P450 Contributions in Hepatic Clearance Predictions: In Vitro-In Vivo Extrapolation as Modelling Approach and Tramadol as Proof-of Concept Compound.
T'jollyn H, Snoeys J, Van Bocxlaer J, De Bock L, Annaert P, Van Peer A, Allegaert K, Mannens G, Vermeulen A, Boussery K. T'jollyn H, et al. Eur J Drug Metab Pharmacokinet. 2017 Jun;42(3):537-543. doi: 10.1007/s13318-016-0355-0. Eur J Drug Metab Pharmacokinet. 2017. PMID: 27317395
15 results